Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026)
Avalo Therapeutics posted quarterly Non Operating Income of $1.3 million for Q1 2026, down 16.03% year-on-year from $1.5 million in Q1 2025, and up 124.86% on a QoQ basis from -$5.2 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Non Operating Income data on file, last reported at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 16.03% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$5.3 million (down 134.29% YoY), and the FY2025 full-year result was -$5.2 million, down 115.43% from the prior year.
- Non Operating Income for Q1 2026 stood at $1.3 million, up from -$5.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $35.9 million in Q3 2024 and bottomed at -$88.5 million in Q1 2024.
- The 5-year median for Non Operating Income is -$26000.0 (2023), against an average of -$5.2 million.
- Peak annual rise in Non Operating Income reached 211182.35% in 2024, while the deepest fall reached 340346.15% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$949000.0 in 2022, then soared by 481.24% to $3.6 million in 2023, then sank by 705.69% to -$21.9 million in 2024, then jumped by 76.45% to -$5.2 million in 2025, then jumped by 124.86% to $1.3 million in 2026.
- The last three Non Operating Income figures came in at $1.3 million (Q1 2026), -$5.2 million (Q4 2025), and -$3000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | -5.16 Mn |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | -21.91 Mn |
| Sep 30, 2024 | 35.88 Mn |
| Mar 31, 2024 | -88.52 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | -17,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -949,000.00 |
| Sep 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -1.15 Mn |
| Mar 31, 2022 | -20,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Dec 31, 2020 | 5.22 Mn |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 398,000.00 |
| Mar 31, 2020 | 7.10 Mn |
| Dec 31, 2019 | -111,560.00 |
| Sep 30, 2019 | 52,711.00 |
| Jun 30, 2019 | 57,322.00 |
| Mar 31, 2019 | -26,760.00 |
| Dec 31, 2018 | 594,995.00 |
| Sep 30, 2018 | -237,848.00 |
| Jun 30, 2018 | -238,489.00 |
| Mar 31, 2018 | -104,998.00 |
| Dec 31, 2017 | 55,577.00 |
| Sep 30, 2017 | 29,451.00 |
| Jun 30, 2017 | -23,520.00 |
| Mar 31, 2017 | -61,509.00 |
| Dec 31, 2016 | 47,642.00 |
| Sep 30, 2016 | -205,429.00 |
| Jun 30, 2016 | -36,123.00 |
| Mar 31, 2016 | -197,647.00 |
| Dec 31, 2015 | 26,933.00 |
| Sep 30, 2015 | 1.27 Mn |
| Jun 30, 2015 | -21,393.00 |
| Mar 31, 2015 | -753,648.00 |
| Dec 31, 2014 | 1.31 Mn |
| Sep 30, 2014 | 158,610.00 |